SCHEMBL2188633

SCHEMBL2188633

CC(C)(C1CCN(c2cccc(C(F)(F)F)c2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.50
CACNA1B Q00975 2/20 0.50
NR1I2 O75469 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
LMNA P02545 1/20 0.40
MCOLN2 Q8IZK6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188801 0.95 CACNA1B (0.49) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2190018 0.93 CACNA1B (0.49) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2188835 0.93 CACNA1B (0.49) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2191790 0.93 CACNA1B (0.49) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2187347 0.90 CACNA1B (0.46) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2190281 0.90 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2189110 0.90 CACNA1B (0.55) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2187123 0.90 CACNA1B (0.55) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2188233 0.88 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2CA12CA1
SCHEMBL2187331 0.87 CACNA1B (0.45) CYP3A4CACNA1BNR1I2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.